The present study investigated the involvement of p62 in cancer progression and the feasibility of small molecule-mediated targeting of p62 for the therapeutic improvement in therapy-resistant cancer cells using head and neck squamous cell carcinoma (HNSCC) as a model. Here, SQSTM1 is linked to head and neck squamous cell carcinoma.